What question did this study set out to answer?

Real-world Efficacy and Safety of Stapokibart in Children and Adolescents with Moderate-to-severe Atopic Dermatitis: A Retrospective Study

View Full Paper

Ask AI

Bookmark

Assess the real-world efficacy and safety of stapokibart in children and adolescents with moderate-to-severe atopic dermatitis.
Retrospective analysis of 55 patients aged 6-17 years treated for 16 weeks.
Weight-tiered dosing: <30 kg received 600 mg loading then 300 mg every 4 weeks, ≥30 kg received 600 mg loading then 300 mg every 2 weeks.
Evaluated disease severity using EASI, SCORAD, IGA, CDLQI, and P-NRS at baseline and weeks 4, 8, 12, and 16.
At week 16, median EASI dropped from 10.0 to 1.95.
Median SCORAD decreased from 46.2 to 13.3.
Mild adverse events occurred in 9.1% of patients, demonstrating good tolerability.

No takes yet. Share an insight, caveat, or question.

Retrospective study shows stapokibart improves atopic dermatitis in children, indicating effective management strategies.

Li et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark